AMEX:VNRX

VolitionRx Limited Releases Annual Corporate Brochure and Video

AUSTIN, Texas, March 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today issued aCorporate Brochure and new Corporate Video detailing the company's mission, strategy, technology, recent...

2020-03-10 20:45 6831

VolitionRx Limited to Present at Conferences in March 2020

AUSTIN, Texas, Mar. 3, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations,Scott Powell, is scheduled to present at five conferences in March 2020. During the conferences, Dr. Powell will outline Volitio...

2020-03-03 21:30 6764

VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update

AUSTIN, Texas, Feb. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year endedDecember 31, 2019. Volition management will host a conference call tomorrow,February 21, at 8:30 a.m. U.S. Easte...

2020-02-21 05:10 9253

VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update

AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunctio...

2020-02-19 05:10 9346

Volition Unveils Its Epigenetic Toolbox

AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that research on its Nu.Q(TM) Capture program has led to the development of a suite of novel epigenetic tools building on the breakthroughs announced last month on its assay platform...

2020-02-18 21:30 7747

VolitionRx Announces Filing of Registration Statements

AUSTIN, Texas, Feb. 7, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has filed registration statements on Form S-3 and Form S-8, respectively, with the Securities and Exchange Commission. The primary purpose of filing the registration statemen...

2020-02-08 06:30 9848

Volition Develops a New Improved Nu.Q™ Assay Format

AUSTIN, Texas, Jan. 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided an update on its Nu Q™ Clinical Assays which use a magnetic particle-based assay format. Volition has completely re-engineered its Nu.Q™ assays leading to a step-change improvement in...

2020-01-13 22:00 15091

VolitionRx Completes Acquisition of Octamer GmbH

AUSTIN, Texas, Jan. 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the closing of the acquisition of the epigenetic reagent company Octamer GmbH ("Octamer") by its subsidiary Belgian Volition SPRL for approximately$725,000, consisting of cash and sh...

2020-01-10 21:00 14026

VolitionRx Limited Announces Strategic Acquisition

AUSTIN, Texas, Dec. 16, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced an agreement by its subsidiary Belgian Volition SPRL to acquire an epigenetic reagent company, Octamer GmbH ("Octamer"), for approximately$725,000 consisting of cash and shares of r...

2019-12-16 21:30 13108

VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test

AUSTIN, Texas, Dec. 5, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it was awarded$820,000 (€740,000 Euros) and Gyros Protein Technologies AB, now part of Mesa Laboratories Inc. (NASDAQ:MLAB) was awarded$230,000 (€206,000 Euros) each in the form ...

2019-12-05 21:30 11302

VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia

AUSTIN, Texas, Dec. 3, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its latest proof of concept study. A single pre-clinical Nu.Q™ assay utilizing a basic microtiter plate platform detected 80% of newly diagnosed Non-Hodgkins Lymphoma ("N...

2019-12-03 21:30 11017

VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update

AUSTIN, Texas, Nov 13, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter endedSeptember 30, 2019. Volition management will host a conference call tomorrow,November 13, at 8:30 a.m. U.S. Eastern ...

2019-11-13 16:54 4810

VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update

AUSTIN, Texas, Nov. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) ("Volition") today announced it will host a conference call onWednesday, November 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2019 in addition to providin...

2019-11-07 21:30 5328

Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video

AUSTIN, Texas, Oct. 29, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the confirmation of a further$500,000 non-dilutive funding in the form of a loan from the Texas A&M SOFINEX funding agency of the Walloon Region to support the development of its sub...

2019-10-29 20:30 5443

Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC

AUSTIN, Texas, Oct. 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") announced today that it (through its subsidiaries) has executed binding agreements contemplated by the previously announced Memorandum of Understanding withTexas A&M University ("Texas A&M"), a memb...

2019-10-26 00:00 7978

Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas

AUSTIN, Texas, Oct. 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical S...

2019-10-18 20:30 9713

Volition Appoints Dr. Phillip Barnes to Board of Directors

AUSTIN, Texas, Oct. 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the appointment of Dr.Phillip Barnes to the Company's Board of Directors as a Non-Executive Director, effectiveOctober 9, 2019. Dr. Barnes was also appointed to the Company's Audit, C...

2019-10-10 04:05 11191

Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

AUSTIN, Texas, Sept. 17, 2019 /PRNewswire/ --  VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.QTM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin. This breakthrough could ...

2019-09-17 20:35 10217

Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer

AUSTIN, Texas, Aug. 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the recent formation of a subsidiary, Volition Veterinary Diagnostics Development LLC ("Volition Veterinary"), and the appointment of animal health expertNathan Dewsbury as its Chief ...

2019-08-08 20:30 6646

VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update

AUSTIN, Texas, Aug. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onTuesday, August 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2019 in addition to providing a business upd...

2019-08-07 20:45 6891
1234